A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.
National Institutes of Health Director Jayanta Bhattacharya, M.D., Ph.D., spent much of a Senate committee hearing dancing around direct answers—except when it came to vaccines, a topic in which he ...
Australia has launched the world’s first clinical trial testing personalized mRNA cancer vaccines in children suffering from ...
QIMR Berghofer scientists have discovered a cancer-fighting RNA molecule that could hold the key to a new way of treating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results